Cargando…

Targeting the non‐ATP‐binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T‐cell lymphoma (CTCL)

We describe here for the first time a lipid‐binding‐domain (LBD) in p38γ mitogen‐activated protein kinase (MAPK) involved in the response of T cells to a newly identified inhibitor, CSH71. We describe how CSH71, which binds to both the LBD and the ATP‐binding pocket of p38γ, is selectively cytotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xu Hannah, Chen, Chih‐Hong, Li, Hongzhi, Hsiang, Jack, Wu, Xiwei, Hu, Weidong, Horne, David, Nam, Sangkil, Shively, Jack, Rosen, Steven T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577799/ https://www.ncbi.nlm.nih.gov/pubmed/34455585 http://dx.doi.org/10.1002/1873-3468.14186

Ejemplares similares

Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma
por: Zhang, Xu Hannah, et al.
Publicado: (2018)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)
por: Gantchev, Jennifer, et al.
Publicado: (2019)

28665 Cutaneous T-cell lymphoma (CTCL) outcomes during COVID-19
por: Garcia-Saleem, Tiffany J., et al.
Publicado: (2021)

The Skin Microbiome in Cutaneous T-Cell Lymphomas (CTCL)—A Narrative Review
por: Łyko, Magdalena, et al.
Publicado: (2022)

Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo
por: Mazuz, Moran, et al.
Publicado: (2020)

JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)
por: Vadivel, Chella Krishna, et al.
Publicado: (2021)

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)
por: Kołkowski, Karol, et al.
Publicado: (2021)

A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL)
por: Tsang, Matthew, et al.
Publicado: (2018)

Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL)
por: Ghazawi, Feras M., et al.
Publicado: (2019)

Cutaneous T-cell lymphoma (CTCL) exacerbation after viral vector COVID-19 vaccination
por: Panou, Evdoxia, et al.
Publicado: (2021)

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel
por: Denis, Daphné, et al.
Publicado: (2019)

International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
por: Geskin, Larisa J, et al.
Publicado: (2021)

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib
por: KieΔling, Michael K., et al.
Publicado: (2017)

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries
por: Assaf, Chalid, et al.
Publicado: (2021)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155
por: Litvinov, Ivan V, et al.
Publicado: (2013)

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description
por: D’Agostino, Paolo, et al.
Publicado: (2020)

Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL
por: Chi, Cheng, et al.
Publicado: (2022)

Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
por: Khan, Shaheer, et al.
Publicado: (2019)

PB2396: HDACI COMBINED WITH LB100 PROMOTES THE OCCURRENCE OF FERROZOSIS IN CTCL
por: Shi, Wenyu
Publicado: (2023)

Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
por: Marzec, Michal, et al.
Publicado: (2011)

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations
por: Crimp, Caitlin, et al.
Publicado: (2022)

Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients
por: Bagdonaite, Ieva, et al.
Publicado: (2015)

Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
Publicado: (2020)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
por: Wang, Zhaohui, et al.
Publicado: (2023)

TMEM244 Is a Long Non-Coding RNA Necessary for CTCL Cell Growth
por: Rassek, Karolina, et al.
Publicado: (2023)

2-Oxoadenosine induces cytotoxicity through intracellular accumulation of 2-oxo-ATP and depletion of ATP but not via the p38 MAPK pathway
por: Asada, Shinji, et al.
Publicado: (2017)

Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

Advanced applications for pocket calculators
por: Gilbert, Jack
Publicado: (1975)

Evaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides).
por: Thayu, M., et al.
Publicado: (1999)

Artemisia herba-alba sesquiterpenes: in silico inhibition in the ATP-binding pocket
por: Mohamed, Tarik A., et al.
Publicado: (2023)

Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study
por: Querfeld, Christiane, et al.
Publicado: (2022)

Atheroprone flow activates inflammation via endothelial ATP-dependent P2X7-p38 signalling
por: Green, Jack P, et al.
Publicado: (2018)

p38γ and p38δ Are Involved in T Lymphocyte Development
por: Risco, Ana, et al.
Publicado: (2018)

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
por: Suri, Ajit, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket
por: D'allard, Diane, et al.
Publicado: (2013)

New Insights into the p38γ and p38δ MAPK Pathways
por: Risco, Ana, et al.
Publicado: (2012)

A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)—A Retrospective Cohort Study
por: Querfeld, Christiane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vc94c359pvvmoe1krgu4or1tim